Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Unknown 1Not yet recruiting 1

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 127Breast Neoplasms 127Ovarian Neoplasms 79Fallopian Tube Neoplasms 45Lung Neoplasms 42Carcinoma, Ovarian Epithelial 30Uterine Cervical Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 27Endometrial Neoplasms 25Triple Negative Breast Neoplasms 23Neoplasm Metastasis 21Neoplasms 20Esophageal Neoplasms 19Stomach Neoplasms 18Esophageal Squamous Cell Carcinoma 15Adenocarcinoma of Lung 13Carcinoma 12Brenner Tumor 11Recurrence 10Urinary Bladder Neoplasms 8Squamous Cell Carcinoma of Head and Neck 8Head and Neck Neoplasms 8Peritoneal Neoplasms 7Inflammatory Breast Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma, Bronchiolo-Alveolar 5Adenocarcinoma 5Melanoma 4Carcinoma, Ductal, Breast 4Adenocarcinoma Of Esophagus 4

Interventions

Paclitaxel 2Carboplatin 2anlotinib 1Nivolumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Squamous Non-small Cell Lung Cancer × Paclitaxel × Clear all
NCT07360132 2026-01-22

Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Shanghai Huaota Biopharmaceutical Co., Ltd.

Phase 3 Not yet recruiting
480 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

NCT04073537 2019-08-29

Study of Anlotinib Hydrochloride Capsule Combined With Chemotherapy in Subjects With Squamous Non-small Cell Lung Cancer

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 3 Unknown
386 enrolled
Thoracic

Squamous Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡